BioWorld MedTech

May 31, 2017

Saluda Medical evokes funding from two industry heavyweights in series D round

Saluda Medical Pty Ltd. is spreading its roots in both the neuromodulation space and the developing bioelectronics medicine market with its latest funding round. Read More

Intuitive surges as robotic surgery acceptance settles in, but can it maintain momentum?

Ra Medical's laser ablative PAD treatment is now FDA-approved

FDA rejects Sunovion Pharmaceuticals' new drug app for COPD drug and nebulizer

Appointments and advancements

Other news to note

Financings

Product briefs

Medical Device Daily's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...